Long-term follow-up from the phase 1/2a PLX120-03 study shows plixorafenib is producing durable responses in BRAF-altered primary central nervous system tumors, including in MAPK inhibitor–naive patients, with no reported evidence of cumulative adverse effects over extended treatment durations. The presented prespecified efficacy subgroup included nine patients with BRAF V600E–mutated, MAPK inhibitor–naive disease. Across the prespecified subgroup, objective response rates reached 67% overall, including 80% in high-grade glioma and 50% in low-grade glioma/glioneuronal tumors. Progression-free survival rates were reported at 56% for a 12-month minimum and 33% for a 24-month minimum, with median treatment duration of 13.8 months (range 2.8 to 61.8+). The developer’s strategy targets BRAF V600 monomers and disrupts mutant dimers to aim to avoid paradoxical MAPK activation and support single-agent use across class 2 and V600 alterations. The dataset also describes retreatment responses in some patients who progressed and later received other MAPK inhibitors. For clinicians, the key signal is persistence of efficacy in a historically difficult-to-treat molecularly defined CNS population without new late safety accumulation in the reported follow-up window.
Get the Daily Brief